IP Library Granted Patent US 8,747,834
Granted Patent B2
US 8,747,834 · App. 13/254,035 · Granted Jun 10, 2014

Methods of treating impaired glucose metabolism via administration of algal biomass

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,747,834
App. No.
13/254,035
Granted
Jun 10, 2014
Kind
B2
Abstract

The invention is directed to methods of using Chlorella protothecoides microalgal biomass in the treatment of individuals having impaired glucose metabolism. In some cases, the patient has impaired fasting glucose, impaired glucose tolerance, or diabetes. In some methods, algal biomass is used to reduce blood glucose and/or body fat in a subject, or to increase the relative abundance of beneficial gut microflora in a subject. In preferred embodiments, the biomass is derived from Chlorella protothecoides cultures grown heterotrophically in which the algal cells comprise at least 15% algal oil by dry weight.

Claims (17)

1. A method of treating a patient having a condition related to impaired glucose metabolism, comprising determining the patient has impaired glucose metabolism and administering to the patient an effective regime of microalgal biomass comprising at least 15% algal oil by dry weight, wherein the microalgal biomass is derived from Chlorella protothecoides and the regime lowers the percentage fat of total body weight in the patient relative to the percentage before the administering step.

2. The method of claim 1 , wherein the microalgal biomass contains 25-75% of algal oil by dry weight.

3. The method of claim 1 , wherein at least 50% by weight of the algal oil is monounsaturated oil.

4. The method of claim 1 , wherein less than 5% by weight of the algal oil is docosahexanoic acid (DHA).

5. The method of claim 1 , wherein the algal oil is predominantly encapsulated in cells of the microalgal biomass.

6. The method of claim 1 , wherein the microalgal biomass is administered as a homogenate.

7. The method of claim 1 , wherein the patient has a condition selected from the group consisting of impaired glucose tolerance, impaired fasting glucose, and/or diabetes.

8. The method of claim 1 , wherein the regime comprises administering the microalgal biomass at a dose of 1-20% of food by weight or calories.

9. The method of claim 1 , wherein the microalgal biomass is administered daily for at least a week.

10. The method of claim 1 , wherein the microalgal biomass is administered with at least one other edible ingredient as a food composition.

11. The method of claim 1 , wherein the patient receives an alternative treatment for impaired glucose metabolism before the administering step and the alternative treatment is reduced or eliminated after the administering step.

12. The method of claim 1 , further comprising monitoring blood glucose levels of the patient, wherein the regime lowers the mean plasma glucose concentration of the patient relative to the concentration before the administering step.

13. The method of claim 1 , wherein the algal biomass is derived from Chlorella protothecoides grown heterotrophically.

14. The method of claim 13 , wherein the Chlorella protothecoides is grown in a culture medium including a feedstock comprising at least one carbon substrate selected from the group consisting of a depolymerized cellulosic material, a 5-carbon sugar, and a 6-carbon sugar.

15. The method of claim 1 , wherein the microalgal biomass is administered in the form of a tablet or capsule.

16. The method of claim 1 , wherein the microalgal biomass is administered in the form of a food product.

17. The method of claim 1 , wherein treating the patient comprises reducing the patient's mean blood glucose level relative to the level before administering the regime.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 3, 2017
From: TERRAVIA HOLDINGS, INC.
To: CORBION BIOTECH, INC.
Reel/Frame 044424/0211 →
CHANGE OF NAME Recorded May 23, 2016
From: SOLAZYME, INC.
To: TERRAVIA HOLDINGS, INC.
Reel/Frame 038794/0867 →